A novel SRSF3 inhibitor, SFI003, exerts anticancer activity against colorectal cancer by modulating the SRSF3/DHCR24/ROS axis

A novel SRSF3 inhibitor, SFI003, exerts anticancer activity against colorectal cancer by modulating the SRSF3/DHCR24/ROS axis

As the modulation of serine/arginine-rich splicing factor 3 (SRSF3) may be therapeutically beneficial to colorectal cancer (CRC) treatment, the identification of novel SRSF3 inhibitors is highly anticipated. However, pharmaceutical agents targeting SRSF3 have not yet been discovered. Here, we propos...

Full description

Bibliographic Details
Main Authors: Chen, Y. (Author), Feng, C. (Author), Guo, X. (Author), Guo, Y. (Author), Li, H. (Author), Meng, F. (Author), Sun, J. (Author), Tian, S. (Author), Wang, M. (Author), Wang, W. (Author), Yang, M. (Author), Zhang, H. (Author), Zhang, Y. (Author), Zhu, Y. (Author)
Format: Article
Language:English
Published: Springer Nature 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items